Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1C | Q14123 | 8/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 7/20 | 0.34 |
| ▸ | PDE1A | P54750 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | HRH1 | P35367 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321250 | 0.92 | PDE1C (0.36) | PDE1CPDE1BPDE1AHRH4 | |
| SCHEMBL21091174 | 0.89 | PDE1C (0.33) | PDE1CPDE1BPDE1AHRH4 | |
| SCHEMBL16748877 | 0.82 | PDE1C (0.44) | PDE1CPDE1BPDE1AKCNH2 | |
| SCHEMBL400651 | 0.81 | PDE1C (0.43) | PDE1CPDE1BPDE1AKCNH2 | |
| SCHEMBL2326369 | 0.81 | PDE1C (0.36) | PDE1CPDE1BPDE1A | |
| SCHEMBL18099738 | 0.80 | PDE1C (0.46) | PDE1CPDE1BPDE1A | |
| SCHEMBL23834518 | 0.80 | PDE1C (0.35) | PDE1CPDE1BPDE1AHRH4 | |
| SCHEMBL2324052 | 0.80 | PDE1C (0.35) | PDE1CPDE1BPDE1AHRH4 | |
| SCHEMBL2324047 | 0.80 | PDE1C (0.35) | PDE1CPDE1BPDE1AHRH4 | |
| SCHEMBL2326452 | 0.80 | HSD11B1 (0.35) | PDE1CPDE1BPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-08-25 | — | — | US | disclosed |
| US-20190177333-A1 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177333-A1 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | PDE1C 3305/4885PDE1B 3091/4885PDE1A 3458/4885 |
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | PDE1C 3232/4885PDE1B 3021/4885PDE1A 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.